Comparative safety analysis of Riluzole, Edaravone and Tofersen in ALS management: insights from FAERS database
This comprehensive evaluation underscores the importance of understanding the distinct AE profiles of Riluzole, Edaravone, and Tofersen in clinical practice, providing valuable insights for personalized ALS management. Future research with rigorous prospective designs is recommended to validate these findings and explore the mechanisms underlying the reported adverse events.
Authors
- Yuanyuan Leng
- Yanan Yu (ORCID: https://orcid.org/0000-0002-8143-6978)
- Ming Yu (ORCID: https://orcid.org/0000-0002-4880-6543)
- Shuang Guan (ORCID: https://orcid.org/0000-0003-4948-167X)
- Jun Liu (ORCID: https://orcid.org/0000-0001-5288-3042)
- Zhong Wang (ORCID: https://orcid.org/0000-0003-0975-9251)
- Yinli Shi (ORCID: https://orcid.org/0000-0001-7186-2503)
- Sicun Wang
- Zhiyong Hou (ORCID: https://orcid.org/0000-0002-6631-6601)
Institutions
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-11-12
- DOI
- https://doi.org/10.3389/fphar.2025.1687698
- Primary Topic
- Amyotrophic Lateral Sclerosis Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China
- China Academy of Chinese Medical Sciences